多参数MRI在活检初治患者中检测疑似前列腺癌的诊断效能:系统评价与Meta分析
该系统评价与Meta分析纳入16项研究共4973例活检初治的疑似前列腺癌男性,评估多参数MRI的诊断准确性。任何前列腺癌的汇总敏感度为82%、特异度为62%,临床显著前列腺癌的汇总敏感度为88%、特异度为64%,SROC曲线下面积分别为0.81和0.90。作者认为多参数MRI可帮助减少不必要的活检并降低漏诊临床显著病例的风险。
要点
- 活检初治患者中,多参数MRI检测临床显著前列腺癌的汇总敏感度为88%、特异度为64%,SROC曲线下面积为0.90。
- 检测任何前列腺癌的汇总敏感度为82%、特异度为62%,SROC曲线下面积为0.81。
- 研究间任何前列腺癌总检出率为57.3%,多参数MRI的阴性似然比在临床显著前列腺癌中为0.20。
核心结论
- 该系统评价与Meta分析提示多参数MRI在活检初治患者中检测前列腺癌有效,尤其对临床显著前列腺癌效果更佳。
- 作者认为多参数MRI可帮助减少不必要的活检并降低漏诊临床显著病例的风险,从而指导知情活检决策。
研究设计与样本
- 研究类型为系统评价与Meta分析,系统检索PubMed、Scopus和Cochrane Library数据库中2013年1月至2024年4月发表的研究。
- 共纳入16项研究、4973例患者,提取数据构建2×2列联表以计算敏感度、特异度、阳性预测值和阴性预测值。
- 采用随机效应模型进行汇总估计,并开展亚组分析,生成SROC曲线以总结总体诊断效能。
诊断标准与关键数值
- 检测任何前列腺癌:汇总敏感度82%(95% CI,80-83%),特异度62%(95% CI,60-64%),阳性似然比1.97(95% CI,1.71-2.26),阴性似然比0.28(95% CI,0.24-0.34),诊断比值比7.34(95% CI,5.60-9.63),SROC曲线下面积0.81。
- 检测临床显著前列腺癌:汇总敏感度88%(95% CI,87-90%),特异度64%(95% CI,63-66%),阳性似然比2.49(95% CI,2.03-3.05),阴性似然比0.20(95% CI,0.16-0.25),诊断比值比13.83(95% CI,9.14-20.9),SROC曲线下面积0.90。
- 研究间任何前列腺癌的总检出率为57.3%。
临床应用与阅片要点
- 原文结论认为多参数MRI可帮助减少不必要的活检并降低漏诊临床显著病例的风险,从而指导知情活检决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: This meta-analysis aimed to assess the diagnostic accuracy of multiparametric MRI (mpMRI) in detecting suspected prostate cancer (PCa) in biopsy-naive men.
MATERIALS AND METHODS: PubMed, Scopus, and the Cochrane Library databases were systematically searched for studies published from January 2013 to April 2024. Sixteen studies comprising 4973 patients met the inclusion criteria. Data were extracted to construct 2×2 contingency tables for sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). A random-effects model was used for pooled estimation, and subgroup analyses were conducted. Summary receiver operating characteristic (SROC) curves were generated to summarize overall diagnostic performance.
RESULTS: The overall detection rate of PCa across studies was 57.3%. For detecting any PCa, mpMRI showed pooled sensitivity of 82% (95% CI, 80-83%) and specificity of 62% (95% CI, 60-64%), with positive likelihood ratio (LR) of 1.97 (95% CI, 1.71-2.26), negative LR of 0.28 (95% CI, 0.24-0.34), and diagnostic odds ratio (DOR) of 7.34 (95% CI, 5.60-9.63), and an area under the SROC curve of 0.81. For clinically significant PCa (csPCa), mpMRI had pooled sensitivity of 88% (95% CI, 87-90%) and specificity of 64% (95% CI, 63-66%), with positive LR of 2.49 (95% CI, 2.03-3.05), negative LR of 0.20 (95% CI, 0.16-0.25), DOR of 13.83 (95% CI, 9.14-20.9), and area under the curve of 0.90.
CONCLUSION: This meta-analysis suggests that mpMRI is effective in detecting PCa in biopsy-naive patients, particularly for csPCa. It can help reduce unnecessary biopsies and lower the risk of missing clinically significant cases, thereby guiding informed biopsy decisions.
引用
- Yang L, Zhang T, Liu S, et al. Diagnostic Performance of Multiparametric MRI for the Detection of suspected Prostate Cancer in Biopsy-Naive Patients: A Systematic Review and Meta-analysis. Acad Radiol. 2024. PMID: 39227219. doi:10.1016/j.acra.2024.08.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。